Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Tracking Crohn's disease just got a whole lot easier. Simplified patient-reported scores — PRO2 and PRO3 — were calculable in over 80% of real-world clinic visits, compared to just 1 in 4 visits for traditional indices like CDAI and HBI. Better yet, they showed strong agreement with those established measures, making them a practical, scalable option for routine and telehealth care.
Tracking Crohn's disease activity in real-world settings has long been a challenge — traditional indices like the Crohn's Disease Activity Index (CDAI) and Harvey-Bradshaw Index (HBI) require lab values and physical exam findings that aren't always available at the point of care. Now, a large study suggests that simpler, patient-reported scores could fill that gap effectively.
Researchers analyzed over 26,000 clinical assessments from patients with Crohn's disease across Australia and New Zealand. They found that PRO2 and PRO3 — scores based on patients' self-reports of stool frequency, abdominal pain, and general well-being — were calculable in more than 80% of visits, versus roughly 25% for CDAI and HBI. Crucially, the simpler scores showed strong agreement with the traditional indices in categorizing disease severity.
By the Numbers:
Why it matters: For clinicians managing Crohn's disease — especially via telehealth — PRO2 and PRO3 offer a reliable, low-burden alternative to data-heavy indices, making consistent disease monitoring far more achievable at scale.
